NCT04821583View on ClinicalTrials.gov

Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study

PHASE3UnknownINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions
Symmetric Lipomatoses, Multiple
Interventions
DRUG

Hydrocortisone

Hydrocortisone is orally administered.

DRUG

Placebo

Placebo is orally administered.

Trial Locations (1)

3015GD

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT04821583 - Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study | Biotech Hunter | Biotech Hunter